Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring

References

• Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993;696:63–87.
   PubMed Web of Science ®Google Scholar
• Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161–73.
   PubMed Web of Science ®Google Scholar
• Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813–21.
   PubMed Web of Science ®Google Scholar
• Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005;80:S191–S200.
   PubMed Web of Science ®Google Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429–55.
   PubMed Web of Science ®Google Scholar
• Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, Venkataramanan R. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005; 45:34–41.
   PubMed Web of Science ®Google Scholar
• Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999;65:640–8.
   PubMed Web of Science ®Google Scholar
• Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, Hutchinson IV, Burckart GJ. A novel variant L263F in human inosine 5’-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007;17:283–90.
   PubMed Web of Science ®Google Scholar
• Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009;9:1607–19.
   PubMed Web of Science ®Google Scholar
• Le MY, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de LB, Rostaing L, Thervet E, Szelag JC, Rerolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7:2496–503.
   PubMed Web of Science ®Google Scholar
• van GT, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le MY, Oellerich M, Holt DW, Tonshoff B, Keown P, Campbell S, Mamelok RD. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008;86: 1043–51.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Le MY, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tonshoff B, Holt DW, Chapman J, Gelder T. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5:341–58.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13–58.
   PubMed Web of Science ®Google Scholar
• Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011–7.
   PubMed Web of Science ®Google Scholar
• Benichou AS, Blanchet B, Conti F, Hornecker M, Bernard D, Taieb F, Scatton O, Abbas H, Harcouet L, Dauphin A, Calmus Y, Tod M. Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. J Clin Pharmacol 2010; 50:1202–10.
   PubMed Web of Science ®Google Scholar
• Svensson JO, Brattstrom C, Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit 1999;21:322–4.
   PubMed Web of Science ®Google Scholar
• Vethe NT, Bergan S. Determination of inosine monophosphate dehydrogenase activity in human CD4 + cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit 2006;28:608–13.
   PubMed Web of Science ®Google Scholar
• Atcheson BA, Taylor PJ, Kirkpatrick CM, Duffull SB, Mudge DW, Pillans PI, Johnson DW, Tett SE. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004;26:284–6.
   PubMed Web of Science ®Google Scholar
• Chiarelli LR, Molinaro M, Libetta C, Tinelli C, Cosmai L, Valentini G, Dal CA, Regazzi M. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Br J Clin Pharmacol 2010;69:38–50.
   PubMed Web of Science ®Google Scholar
• Raggi MC, Siebert SB, Steimer W, Schuster T, Stangl MJ, Abendroth DK. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients’ outcomes after renal transplantation. Transplantation 2010;90:1536–41.
   PubMed Web of Science ®Google Scholar
• Weimert NA, Derotte M, Alloway RR, Woodle ES, Vinks AA. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 2007;29:141–9.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Goebel J, Thogersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol 2011;51:309–20.
   PubMed Web of Science ®Google Scholar